Alkylxanthines as research tools

Journal of the Autonomic Nervous System

Volumn 81, Issue 1-3, 2000, Pages 44-52

  Daly, John W ^a  

^a Human Motor Control Section   (United States)

Author keywords

Caffeine; Methylxanthines; Pharmacological effects

Indexed keywords

8 PHENYLTHEOPHYLLINE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; CAFFEINE; ENPROFYLLINE; ISOBUTYLMETHYLXANTHINE; PHOSPHODIESTERASE; THEOPHYLLINE; XANTHINE DERIVATIVE;

AUTONOMIC NERVOUS SYSTEM FUNCTION; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CHEMICAL BINDING; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW;

EID: 0034601164     PISSN: 01651838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1838(00)00110-7     Document Type: Article

References (103)

1. Akasu T., Karczmar A.G. Effects of 1-methyl-3-isobutyl xanthine (MIX) on amphibian neuromyal transmission. J. Pharmacol. Exp. Ther. 213:1980;586-595.
2. Ali H., Müller C.E., Daly J.W., Beaven M.A. Methylxanthines block antigen-induced responses in RBL-2H3 cells independently of adenosine receptors or cyclic AMP: evidence for inhibition of antigen binding to IgE. J. Pharmacol. Exp. Ther. 258:1991;954-962.
3. Avidor T., Clementi E., Schwartz L., Atlas D. Caffeine-induced transmitter release is mediated via ryanodine-sensitive channel. Neurosci. Lett. 165:1994;133-136.
4. 2A adenosine receptor antagonists. Curr. Med. Chem. 2:1995;707-722.
5. Beavo J.A., Reifsnyder D.H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci. 11:1990;150-155.
6. Beavo J.A., Rogers N.L., Crofford O.B., Hardman J.G., Sutherland E.W., Newman E.V. Effects of xanthine derivatives on lipolysis and on adenosine 3′,5′-monophosphate phosphodiesterase activity. Mol. Pharmacol. 6:1970;597-603.
7. Bianchi C.P. Effects of caffeine on radiocalcium movement in the frog sartorius. J. Gen. Physiol. 44:1961;845-858.
8. 2+ channel in rat cerebellum is inhibited by caffeine. Biochem. J. 282:1992;309-312.
9. Bruns R.F. Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts. Biochem. Pharmacol. 30:1981;325-333.
10. 3H-phenyl]xanthine. Proc. Natl. Acad. Sci. USA. 77:1980;5547-5551.
11. 3H]NECA in rat striatal membranes. Mol. Pharmacol. 29:1986;331-346.
12. 1-selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes. Naunyn-Schmiedeberg's Arch. Pharmacol. 335:1987;59-63.
13. Burnstock G. A basis for distinguishing two types of purinergic receptors. Straub R.W., Bolis I.L. Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach. 1978;107-118 Raven Press, New York.
14. 2+-release by methylxanthine analogues. J. Med. Chem. 42:1999;2527-2534.
15. Chappe V., Mettey V., Vierfond J.M., Hanrahan J.W., Gola M., Verrier B., Becq F. Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel. Br. J. Pharmacol. 123:1998;683-693.
16. Choi O.H., Shamim M.T., Padgett W.L., Daly J.W. Caffeine and theophylline analogues: correlation of behavioral effects with activity as adenosine receptor antagonists and as phosphodiesterase inhibitors. Life Sci. 43:1988;387-398.
17. Combettes L., Berthon B., Claret M. Caffeine inhibits cytosolic calcium oscillations induced by noradrenaline and vasopressin in rat hepatocytes. Biochem. J. 301:1994;737-744.
18. Daly J.W. Mechanism of action of caffeine. Garattini S. Caffeine, Coffee, and Health. 1993;97-150 Raven Press, New York.
19. Daly J.W., Butts-Lamb P., Padgett W. Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines. Cell. Mol. Neurobiol. 3:1983;69-80.
20. Daly J.W., Hide I., Müller C.E., Shamim M. Caffeine analogs: structure-activity relationships at adenosine receptors. Pharmacology. 42:1991;309-321.
21. Daly J.W. Pharmacology of caffeine. Tarter R.E., Ammerman R.T., Ott P.J. Handbook of Substance Abuse: Neurobehavioral Pharmacology. 1998;53-68 Plenum Press, New York.
22. 2-adenosine receptors. J. Med. Chem. 28:1985;487-492.
23. DeGubareff T., Sleator W. Jr. Effects of caffeine on mammalian atrial muscle and its interaction with adenosine and calcium. J. Pharmacol. Exp. Ther. 148:1965;202-214.
24. A responsiveness in rat identified native primary afferents. Eur. J. Pharmacol. 203:1991;137-140.
25. 2+ oscillations in HeLa cells are sensitive to methylxanthines but insensitive to ryanodine. Pflügers Arch. 426:1994;129-138.
26. 2+-release channels. Trends Pharmacol. Sci. 15:1994;145-149.
27. 1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc. Natl. Acad. Sci. USA. 89:1992;5562-5566.
28. Ercan-Fang N., Nuttall F.Q. The effect of caffeine and caffeine analogs on rat liver phosphorylase a activity. J. Pharmacol. Exp. Ther. 280:1997;1312-1318.
29. Fan S., Smith M.L., Rivet D.J. II, Duba D., Zhan Q., Kohn K.W., Fornace A.J. Jr., O'Connor P.M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 55:1995;1649-1654.
30. 2B receptors. Pharmacol. Rev. 49:1997;381-402.
31. Frank G.B. Utilization of bound calcium in the action of caffeine and certain multivalent cations on skeletal muscle. J. Physiol. 163:1962;254-268.
32. Fredholm B.B., Lindgren E. Inhibition of soluble 5′-nucleotidase from rat brain by different xanthine derivatives. Biochem. Pharmacol. 32:1983;2832-2834.
33. Fredholm B.B., Hedqvist P., Vernet L. Effect of theophylline and other drugs on rabbit renal cyclic nucleotide phosphodiesterase, 5′-nucleotidase and adenosine deaminase. Biochem. Pharmacol. 27:1978;2845-2850.
34. Fredholm B.B., Lindström K., Wallman-Johansson A. Propentofylline and other adenosine transport inhibitors increase the efflux of adenosine following electrical or metabolic stimulation of rat hippocampal slices. J. Neurochem. 62:1994;563-573.
35. 2A receptors and the actions of caffeine. Okada Y. The Role of Adenosine in the Nervous System. 1997;51-74 Elsevier Science, Amsterdam.
36. Geis U., Grahner B., Pawlowski M., Drabczynska M., Müller C.E. Tricyclic theophylline derivatives with high water-solubility: structure-activity relationships at adenosine receptors, phosphodiesterases, and benzodiazepine binding sites. Pharmazie. 50:1995;333-336.
37. 1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator ΔF508 mutation. Biochemistry. 34:1995;9079-9087.
38. 2+-permeable, nonselective cation channel in smooth muscle cells. J. Gen. Physiol. 104:1994;375-394.
39. Gupta M.P., Makino N., Takeo S., Kaneko M., Dhalla N.S. Cardiac sarcolemma as a possible site of action of caffeine in rat heart. J. Pharmacol. Exp. Ther. 255:1990;1188-1194.
40. + current in guinea pig single ventricular cells. Am. J. Physiol. 261:1991;H1855-H1863.
41. Haws C.M., Nepomuceno I.B., Krouse M.E., Wakelee H., Law T., Xia Y., Nguyen H., Wine J.J. ΔF508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines. Am. J. Physiol. 270:1996;C1544-C1555.
42. 2+ release in permeabilized vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 194:1993;726-732.
43. 3H]Xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: an antagonist radioligand for adenosine receptors. Proc. Natl. Acad. Sci. USA. 83:1986;4089-4093.
44. 2-selective adenosine antagonists. J. Med. Chem. 36:1993;1333-1342.
45. 1 adenosine receptors. Biochemistry. 34:1995;9088-9094.
46. Jiang X., Lim L.Y., Daly J.W., Li A.H., Jacobson K.A., Roberge M. Structure-activity relationships for G2 checkpoint inhibition by caffeine analogs. Int. J. Oncol. 2000;. In press.
47. Kardos J., Blandl T. Inhibition of a gamma aminobutyric acid A receptor by caffeine. Neuroreports. 5:1994;1249-1252.
48. 3 adenosine receptors. J. Med. Chem. 37:1994;3373-3382.
49. 2B adenosine receptors. Drug Dev. Res. 47:1999;178-188.
50. 3 cells. Pflügers Arch. 426:1994;12-20.
51. Kunzelmann K., Briel M., Schreiberg R., Ricken S., Nitschke R., Greger R. No evidence for direct activation of the cystic fibrosis transmembrane conductance regulator by 8-cyclopentyl-1,3-dipropylxanthine. Cell. Physiol. Biochem. 8:1998;185-193.
52. Levi-Schaffer F., Touitou E. Xanthines inhibit 3T3 fibroblast proliferation. Skin Pharmacol. 4:1991;286-290.
53. q in human embryonic kidney 293 cells and HMC-1 mast cells. Mol. Pharmacol. 56:1999;705-713.
54. 2+ release channel. Pharmacology. 54:1997;135-143.
55. Londos C., Wolff J. Two distinct adenosine-sensitive sites on adenylate cyclase. Proc. Natl. Acad. Sci. USA. 74:1977;5482-5486.
56. A receptor complex: alterations in receptor function but not ligand binding. Eur. J. Pharmacol. 172:1989;453-459.
57. Marangos P.J., Paul S.M., Parma A.M., Goodwin F.K., Syapin P., Skolnick P. Purinergic inhibition of diazepam binding to rat brain (in vitro). Life Sci. 24:1979;851-858.
58. McPherson P.S., Kim Y.-K., Valdivia H., Knudson C.M., Takekura H., Franzini-Armstrong C., Coronado R., Campbell K.P. The brain ryanodine receptor: a caffeine-sensitive calcium release channel. Neuron. 7:1991;17-25.
59. 2+ release from inositol trisphosphate-sensitive stores in rat hepatocytes. J. Physiol. 455:1992;623-640.
60. 1-adenosine receptor antagonists. Exp. Opin. Ther. Patents. 7:1997;419-440.
61. Müller C.E., Daly J.W. Stimulation of calcium release by caffeine analogs in pheochromocytoma cells. Biochem. Pharmacol. 46:1993;1825-1829.
62. 2A-selective adenosine receptor antagonists. J. Med. Chem. 40:1997;4396-4405.
63. Musk S.R.R., Steel G.C. Override of the radiation-induced mitotic block in human tumour cells by methylxanthines and its relationship to the potentiation of cytotoxicity. Int. J. Radiat. Biol. 57:1990;1105-1112.
64. Nicholson C.D., Jackman S.A., Wilke R. The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re-uptake site. Br. J. Pharmacol. 97:1989;889-897.
65. 2 receptor antagonist. Eur. J. Pharmacol. 267:1994;335-341.
66. Parker I., Ivorra I. Caffeine inhibits inositol trisphosphate-mediated liberation of intracellular calcium in Xenopus oocytes. J. Physiol. 433:1991;229-240.
67. Parkinson F.E., Rudolphi K.A., Fredholm B.B. Propentofylline: a nucleoside transport inhibitor with neuroprotective effects in cerebral ischemia. Gen. Pharmacol. 25:1994;1053-1058.
68. i. Mol. Pharmacol. 34:1988;37-41.
69. 2+, caffeine, and adenine nucleotides. Mol. Pharmacol. 31:1987;232-238.
70. Rall T.W., Sutherland E.W. Formation of a cyclic adenine ribonucleotide by tissue particles. J. Biol. Chem. 232:1958;1065-1076.
71. Reiser M.A., D'Souza T., Dryer S.E. Effects of caffeine and 3-isobutyl-1-methylxanthine on voltage-activated potassium currents in vertebrate neurones and secretory cells. Br. J. Pharmacol. 118:1996;2145-2151.
72. Robeva A.S., Woodard R.L., Jin X., Gao Z., Battacharya S., Taylor H.E., Rosin D.L., Linden J. Molecular characterization of recombinant human adenosine receptors. Drug. Dev. Res. 39:1996;243-252.
73. Rosenthal L.A., Taub D.D., Moors M.A., Blank K.J. Methylxanthine-induced inhibition of the antigen- and superantigen-specific activation of T and B lymphocytes. Immunopharmacology. 24:1992;203-217.
74. 2+ release channel of skeletal muscle sarcoplasmic reticulum by caffeine and related compounds. Arch. Biochem. Biophys. 267:1988;75-86.
75. Rowley R., Zorch M., Leeper D.B. Effect of caffeine on radiation-induced mitotic delay: delayed expression of G2 arrest. Radiat. Res. 97:1984;178-185.
76. Russell K.J., Wiens L.W., Demers G.W., Galloway D.A., Le T., Rice G.C., Bianco J.A., Singer J.W., Groudine M. Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthines. Int. J. Radiat. Oncol. Biol. Phys. 36:1996;1099-1106.
77. 3 adenosine receptor. Proc. Natl. Acad. Sci. USA. 90:1993;10365-10369.
78. 2+ oscillations in single rat hepatocytes. Biochem. Biophys. Res. Commun. 198:1994;728-733.
79. Sarkaria J.N., Busby E.C., Tibbetts R.S., Roos P., Taya Y., Karnitz L.M., Abraham R.T. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 59:1999;4375-4382.
80. Sattin A., Rall T.W. The effect of adenosine and adenine nucleotides on the cyclic 3′,5′-phosphate content of guinea pig cerebral cortex slices. Mol. Pharmacol. 6:1970;13-23.
81. Seale T.W., Abla K.A., Shamim M.T., Carney J.M., Daly J.W. 3,7-Dimethyl-1-propargylxanthine: a potent and selective in vivo antagonist of adenosine analogs. Life Sci. 43:1988;1671-1684.
82. 2+ mobilization in rat salivary acinar cells. Am. J. Physiol. 276:1999;C915-C922.
83. Sesardic D., Boobis A.R., Murray B.P., Murray S., Sequara J., De la Torre R., Davíes D.S. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br. J. Clin. Pharmacol. 29:1990;651-663.
84. Shamim M.T., Ukena D., Padgett W.L., Daly J.W. Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono- di-, and trisubstituted alkylxanthines with substitution at the 1-, 3- and 7-positions. J. Med. Chem. 32:1989;1231-1237.
85. 1-adenosine receptors. J. Med. Chem. 31:1988;613-617.
86. Smellie F.W., Daly J.W., Wells J.M. 1-Isoamyl-3-isobutylxanthine: a remarkably potent agent for potentiation of norepinephrine, histamine, and adenosine-elicited accumulation of cyclic AMP in brain slices. Life Sci. 25:1979;1917-1924.
87. Smellie F.W., Davis C.W., Daly J.W., Wells J.N. Alkylxanthines: inhibition of adenosine-elicited accumulation of cyclic AMP in brain slices and of brain phosphodiesterase activity. Life Sci. 24:1979;2475-2482.
88. Snyder S.H., Katims J.J., Annau Z., Bruns R.F., Daly J.W. Adenosine receptors and behavioral actions of methylxanthines. Proc. Natl. Acad. Sci. USA. 78:1981;3260-3264.
89. Strinden S.T., Stellwagen R.H. Inhibition of guanylate cyclases by methylxanthines and papaverine. Biochem. Biophys. Res. Commun. 123:1984;1194-1200.
90. Sutherland E.W., Rall T.W. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J. Biol. Chem. 232:1958;1077-1091.
91. 3H]-γ-aminobutyric acid receptor binding to rat brain membranes. Biochem. Pharmacol. 29:1980;1217-1220.
92. 2+ signal in mouse pancreatic acinar cells by blocking inositol trisphosphate production. J. Biol. Chem. 267:1992;23467-23470.
93. 2+ pool depletion. J. Biol. Chem. 270:1995;26790-26793.
94. Ukena D., Schudt C., Sybrecht G.W. Adenosine receptor-blocking xanthines as inhibitors of phosphodiesterase isozymes. Biochem. Pharmacol. 45:1993;847-851.
95. - currents in freshly dissociated rat hippocampal neurones. Br. J. Pharmacol. 109:1993;459-465.
96. Usachev Y., Verkhratsky A. IBMX induces calcium release from intracellular stores in rat sensory neurones. Cell Calcium. 17:1995;197-206.
97. in. Pflügers Arch. Eur. J. Physiol. 430:1995;420-428.
98. Van Calker D., Müller M., Hamprecht B. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J. Neurochem. 33:1979;999-1005.
99. Wells J.N., Garst J.E., Kramer G.L. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from pig coronary arteries by 1,3-disubstituted and 1,3,8-trisubstituted xanthines. J. Med. Chem. 24:1981;954-958.
100. Whorton A.R., Collawn J.R., Montgomery M.E., Young S.L., Kent R.S. Arachidonic acid metabolism in cultured aortic endothelial cells. Effect of cAMP and 3-isobutyl-1-methylxanthine. Biochem. Pharmacol. 34:1985;119-123.
101. Windmeier C., Gressner A.M. Effect of pentoxifylline on the fibrogenic functions of cultured rat liver fat-storing cells and myofibroblasts. Biochem. Pharmacol. 51:1996;577-584.
102. cdc2 kinase. Nature Med. 2:1996;1140-1143.
103. Yoshino M., Matsufuji Y., Yabu H. Voltage-dependent suppression of calcium current by caffeine in single smooth muscle cells of the guinea-pig urinary bladder. Naunyn-Schmiedeberg's Arch. Pharmacol. 353:1996;334-341.